CDMO News
Brexogen Signs Landmark Licensing Agreement with BMI Korea for Exosome Therapeutic
Brexogen, a biotechnology company specialising in exosome-based therapeutics, has signed a licensing and technology transfer agreement with BMI Korea for BxC-I17e. The agreement represents the first major licensing deal for an exosome therapeutic in Korea and marks a key milestone in the
20 February 2025